Acer Therapeutics Inc (fka ACER)

[green maschine]

Q4 2020 And Recent Highlights

ACER-001
– Signed an Option Agreement with Relief Therapeutics Holding AG on January 25, 2021, providing Relief with exclusivity until June 30, 2021, for the right to pursue a potential collaboration and license agreement for worldwide development and commercialization for ACER-001. And in return, Acer received a $1 million upfront nonrefundable payment and a $4 million secured loan from Relief

– Announced in February 2021 topline results from Acer’s bioequivalence trial in which ACER-001 showed similar relative bioavailability compared to BUPHENYL® (sodium phenylbutyrate) under fed conditions
EDSIVO (celiprolol)

– Announced in December 2020 publication by Swedish investigators of additional long-term data from COL3A1-positive vascular Ehlers-Danlos Syndrome (vEDS) patients in the European Journal of Vascular and Endovascular Surgery entitled “Celiprolol Treatment in Patients with Vascular Ehlers-Danlos Syndrome”

?- Submitted a Type B meeting request to the FDA in February 2021 to discuss Acer’s proposed plan to collect additional data and provide confirmatory evidence in support of celiprolol’s potential benefit in treating COL3A1-positive vEDS patients

ACER-801 (osanetant)

– Completed active pharmaceutical ingredient (API) manufacturing and advanced other development activities to support an Investigational New Drug Application (IND) submission

Corporate

– Promoted Jefferson Davis to Chief Business Officer in February 2021. A veteran life science executive and transaction specialist with over 25 years of experience in business and corporate development, Mr. Davis has led or supported over 40 transactions with an aggregate value of more than $2 billion across all major therapeutic platforms, including antibodies, small molecules, aptamers, gene therapy, vaccines, and proteins...

[color=greenFull Story: https://pulse2.com/acer-stock-price-nasdaq-acer-therapeutics-increases-over-100-pre-market-what-you-should-know-about-the-company/][/color]